RT Journal Article
SR Electronic
T1 Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.12.20151407
DO 10.1101/2020.07.12.20151407
A1 Bošnjak, Berislav
A1 Stein, Saskia Catherina
A1 Willenzon, Stefanie
A1 Cordes, Anne Katrin
A1 Puppe, Wolfram
A1 Bernhardt, Günter
A1 Ravens, Inga
A1 Ritter, Christiane
A1 Schultze-Florey, Christian R.
A1 Gödecke, Nina
A1 Martens, Jörg
A1 Kleine-Weber, Hannah
A1 Hoffmann, Markus
A1 Cossmann, Anne
A1 Yilmaz, Mustafa
A1 Pink, Isabelle
A1 Hoeper, Marius M.
A1 Behrens, Georg M.N.
A1 Pöhlmann, Stefan
A1 Blasczyk, Rainer
A1 Schulz, Thomas F.
A1 Förster, Reinhold
YR 2020
UL http://medrxiv.org/content/early/2020/07/14/2020.07.12.20151407.abstract
AB Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells using surface-expressed angiotensin-converting enzyme 2 (ACE2). We developed a surrogate neutralization test (sVNT) to assess at what degree serum antibodies interfere with the binding of SARS-CoV-2-S-RBD to ACE2. The sVNT revealed neutralizing anti-SARS-CoV-2-S antibodies in the sera of 90% of mildly and 100% of severely affected coronavirus-disease-2019 (COVID-19) convalescent patients. Importantly, sVNT results correlated strongly to the results from pseudotyped-vesicular stomatitis virus-vector-based neutralization assay and to levels of anti-SARS-CoV-2-S1 IgG and IgA antibodies. Moreover, levels of neutralizing antibodies also correlated to duration and severity of clinical symptoms, but not patient age or gender. These findings together with the sVNT will not only be important for evaluating the prevalence of neutralizing antibodies in a population but also for identifying promising plasma donors for successful passive antibody therapy.Competing Interest StatementThe authors have declared no competing interest.Funding Statement: This work was supported by Deutsche Forschungsgemeinschaft, DFG Excellence Strategy EXC 2155 RESIST Project ID39087428 and by funds of the state of Lower Saxony (1476103184 CORONA11/20) to RF and (1476103184 CORONA12/20) to TFS and by funds of BMBF (RAPID consortium, 01K11723D).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies investigating serum samples from healthy controls and COVID-19 patients were approved by the HMS institutional review board (#9001_BO_K2020 and #7901_BO_K2018).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request to the corresponding authors.